Latest News
CrossBridge Bio to be acquired by Eli Lilly
14 April 2026 - CrossBridge Bio Inc, a pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs), announced on Tuesday that it has entered into a definitive agreement to be acquired by pharmaceutical c...
Groupe Rocher partners with Dassault Systèmes to accelerate cosmetics innovation using virtual twin technology
14 April 2026 - French software developer Dassault Systèmes (Euronext Paris:DSY) and beauty and wellness company Groupe Rocher on Tuesday announced a collaboration to enhance research and development through the deployment of virtual twin tech...
hVIVO signs influenza human challenge trial agreement with Traws Pharma
14 April 2026 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials, announced on Tuesday that it has signed a clinical trial agreement with Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel th...
IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination
14 April 2026 - US precision medicine oncology company IDEAYA Biosciences Inc (NASDAQ:IDYA) and French pharmaceutical company Servier announced on Monday positive topline results from their Phase 2/3 registrational trial, OptimUM-02, evaluating darov...
Kazia Therapeutics in-licenses SETDB1 inhibitor drug development platform
14 April 2026 - Australian oncology company Kazia Therapeutics Limited (Nasdaq:KZIA) announced on Monday the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.The platform includes use of an AI-...